Medchemexpress LLC Rentosertib | 2828567-39-9 | 99.96% | 487.57 | 250 MG

Supplier:  Medchemexpress LLC 250MGHY160623

Rentosertib (INS018 055) (compound 112) is an orally active TNIK and MAP4K4 inhibitor with IC50 values of 12-120 nM for both targets. It is for research use only.

• Orally active TNIK and MAP4K4 inhibitor.
• Reduces TGF-β-induced α-SMA protein expression with an IC50 of 27.14 nM in MRC-5 cells.
• Decreases N-cadherin and p-SMAD2/SMAD3 expression, increases E-cadherin expression, and inhibits TGF-β-induced epithelial-to-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT) in A549 cells.
• Improves lung function and ameliorates pulmonary fibrosis in Bleomycin-administrated mouse models (3-30 mg/kg, po, twice daily for 2 weeks).
• Reduces lymphocytes in bronchoalveolar lavage fluid (BALF), inhibits pro-inflammatory cytokines, and exhibits anti-inflammatory effects in LPS-induced mouse acute lung injury models (3-30 mg/kg, po, single dose).

Catalog No. 50-003-94309